Tucotuzumab celmoleukin

Tucotuzumab celmoleukin (EMD 273066) is an immunocytokine fusion agent targeting the epithelial cell adhesion molecule (EpCAM) . Tucotuzumab celmoleukin binds to EpCAM and delivers IL-2 to the tumor microenvironment, which can activate cytotoxic effector cells, such as CD8+ T cells and natural killer (NK) cells. Tucotuzumab celmoleukin is promising for research of EpCAM-positive cancers, such as colorectal cancer and prostate cancer[1][2].

Product Specifications

CAS Number

[339986-90-2]

Product Name Alternative

EMD 273066; huKS-IL2

UNSPSC

12352203

Target

Interleukin Related

Related Pathways

Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Smiles

[Tucotuzumabcelmoleukin]

References & Citations

[1]Eyvazi S, et al. Antibody Based EpCAM Targeted Therapy of Cancer, Review and Update. Curr Cancer Drug Targets. 2018;18 (9) :857-868.|[2]Wang Z, et al. High-Affinity Fully Human Anti-EpCAM Antibody with Biased IL-2 Exhibits Potent Antitumor Activity. Biomolecules. 2024 Nov 2;14 (11) :1399.